更年期激素治疗和乳腺癌:平衡风险和益处
Rishitha Bollam1, Jana Karam2, Chrisandra Shufelt3
1Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
Maturitas
|February 25, 2026
概括
更年期激素治疗有效地治疗血管运动症状,并预防骨质损失. 乳腺癌风险因配方,持续时间和患者因素而异,仅用雌激素治疗可能会降低发病率和死亡率.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 更年期激素治疗 (MHT) 是治疗血管运动症状和预防骨损失的最有效方法.
- 对乳腺癌风险的担忧在历史上影响了MHT安全感知.
- 最近的证据提升了对MHT乳腺癌风险的理解,突出了配方和持续时间的影响.
研究的目的:
- 综合目前关于MHT益处和风险的证据,重点关注乳腺癌.
- 分析影响MHT结果的风险修饰因素,包括配方,持续时间,时间和路径.
- 引导基于证据的临床决策在更年期管理.
主要方法:
- 对过去二十年累积的证据进行叙述性审查.
- 对激素治疗配方和孕激素类型的观察数据的分析.
- 综合研究检查启动时间和管理途径的研究.
主要成果:
- 仅用雌激素治疗可以减少乳腺癌发病率和死亡率.
- 结合性雌激素-孕激素治疗与乳腺癌风险增加有关.
- 微化孕激素可能比合成孕激素提供更有利的乳腺癌风险概况.
- 时间,持续时间和服用途径会影响MHT的结果.
结论:
- 对于更年期症状和骨健康,MHT提供了显著的好处.
- 与MHT相关的乳腺癌风险是微妙的,取决于特定的治疗方案和患者因素.
- 个性化MHT选择,考虑到风险修饰因素,对于最佳的绝经管理至关重要.
相关概念视频
Menopause
5.1K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
5.1K
Hormonal Regulation of the Menstrual Cycle
1.9K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
1.9K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
503
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
503
Hormonal Control of the Ovarian Cycle
7.2K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
7.2K
Mitral Valve Prolapse III: Nursing Management
474
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
474
Hazard Ratio
661
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
661


